Objective To investigate effect of cassava RS3 resistant starch(Ce-RS3)on serum homocysteine(Hcy)level in patients with atherosclerotic cerebral infarction(ACI)during the recovery period.Methods A total of 55 patients with ACI at the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine from October 2023 to October 2024 were selected as subjects.They were devieded into observation group(n=28)and control group(n=27)using a random number table.The control group received atorvastatin calcium,phospholipids,and aspirin,while the observation group received atorvastatin calcium,phospholipids,aspirin,and Ce-RS3.After 12 weeks of treatment,homocysteine(Hcy)levels,carotid plaque diameter,National Institutes of Health stroke scale(NIHSS)scores,Barthel index(BI)scores,and traditional Chinese medicine(TCM)syndrome scores were compared between two groups.Results After treatment,the serum Hcy levels decreased and carotid plaque size reduced in both groups,with the NIHSS scores and TCM syndrome scores also decreased,and observation group was lower than control group(P＜0.05).After treatment,the BI score increased,with observation group higher than control group(P＜0.05).Conclusion The use of Ce-RS3 in the recovery phase of patients with ACI can effectively improve neurological function and enhance treatment efficacy.

Human embryo is regarded as the middle body between subject and object, which is the main cognition of the ethical status of embryo. It is considered that personhood of an embryo is gradually acquired in the process of its development. From an ethical point of view, when the primitive streak of an embryo is generated at 2 weeks after fertilization, the "human" property is considered to be generated, and this time limit should be followed in scientific research. It is unacceptable that in vitro research uses embryos which have "human" property. Research for the purpose of obtaining offspring must be in accordance with the ethical guidelines of assisted reproductive technology. Reproductive gene editing and reproductive cloning are forbidden. Construction of chimeric embryos between individuals and species violates the principle of respect for human beings. Embryos should not be cultured in vitro for more than 2 weeks of embryo age. Ethical supervision is an important way to ensure the observance of ethical norms in embryology research, including self-supervision, supervision by public opinions, ethical review and supervision of ethics committee, regulation and system supervision This article reviews the ethical considerations and supervision of the use of human gametes and in vitro embryos for scientific research.

Human embryo is regarded as the middle body between subject and object, which is the main cognition of the ethical status of embryo. It is considered that personhood of an embryo is gradually acquired in the process of its development. From an ethical point of view, when the primitive streak of an embryo is generated at 2 weeks after fertilization, the "human" property is considered to be generated, and this time limit should be followed in scientific research. It is unacceptable that in vitro research uses embryos which have "human" property. Research for the purpose of obtaining offspring must be in accordance with the ethical guidelines of assisted reproductive technology. Reproductive gene editing and reproductive cloning are forbidden. Construction of chimeric embryos between individuals and species violates the principle of respect for human beings. Embryos should not be cultured in vitro for more than 2 weeks of embryo age. Ethical supervision is an important way to ensure the observance of ethical norms in embryology research, including self-supervision, supervision by public opinions, ethical review and supervision of ethics committee, regulation and system supervision This article reviews the ethical considerations and supervision of the use of human gametes and in vitro embryos for scientific research.

Objective To investigate effect of cassava RS3 resistant starch(Ce-RS3)on serum homocysteine(Hcy)level in patients with atherosclerotic cerebral infarction(ACI)during the recovery period.Methods A total of 55 patients with ACI at the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine from October 2023 to October 2024 were selected as subjects.They were devieded into observation group(n=28)and control group(n=27)using a random number table.The control group received atorvastatin calcium,phospholipids,and aspirin,while the observation group received atorvastatin calcium,phospholipids,aspirin,and Ce-RS3.After 12 weeks of treatment,homocysteine(Hcy)levels,carotid plaque diameter,National Institutes of Health stroke scale(NIHSS)scores,Barthel index(BI)scores,and traditional Chinese medicine(TCM)syndrome scores were compared between two groups.Results After treatment,the serum Hcy levels decreased and carotid plaque size reduced in both groups,with the NIHSS scores and TCM syndrome scores also decreased,and observation group was lower than control group(P＜0.05).After treatment,the BI score increased,with observation group higher than control group(P＜0.05).Conclusion The use of Ce-RS3 in the recovery phase of patients with ACI can effectively improve neurological function and enhance treatment efficacy.

Objective:To follow-up the previous phase Ⅲ clinical trial of recombinant human follicle-stimulating hormone (Follitrope ?), and to evaluate the cumulative pregnancy rate, the cumulative live birth rate, and the neonatal outcomes of subjects. Methods:The phase Ⅲ clinical study of Follitrope ? in China (CTR20150341/CTR20150341, May 15, 2015—June 27, 2016) was followed up until December 31, 2022. Patients were divided into Follitrope ? group and Gonal-F ? group. According to the age, patients were divided into three subgroups: 20-30 years old subgroup, 31-35 years old subgroup and 36-39 years old subgroup. Cumulative pregnancy rate, cumulative live birth rate, number of embryos transferred per cycle, live births per embryo transfer cycle, live births per oocyte retrieved, and neonatal characteristics were analyzed. Results:A total of 446 patients were included in the analysis, of which 336 (75.3%) were in the Follitrope ? group and 110 (24.7%) in the Gonal-F ? group, with a follow-up period of 6.5 years. There were no statistically significant differences between the Follitrope ? group and the Gonal-F ? group in terms of cumulative pregnancy rate and cumulative live birth rate (all P>0.05). Similar cumulative pregnancy rates and cumulative live birth rates were observed between the two groups within each age subgroup (all P>0.05). In the 36-39 years old subgroup, the Follitrope ? group showed a trend towards higher cumulative pregnancy rate [60.0% (12/20)] and cumulative live birth rate [55.0% (11/20)] compared with the Gonal-F ? group [28.6% (2/7), 14.3% (1/7)], however, none of the differences were statistically significant (all P>0.05). Twin pregnancy rates, live births per embryo, live birth per oocyte, newborn gender, birth weight, and birth defect rates were similar between the Follitrope ? group and the Gonal-F ? group without statistically significant differences (all P>0.05). Conclusion:The safety and effectiveness of Follitrope ? in controlled ovarian hyperstimulation are similar to those of Gonal-F ?. Compared with Gonal-F ?, there is a trend toward higher cumulative pregnancy rates and cumulative live birth rates in elderly patients with Follitrope ?, although there is no statistical difference.

Objective:To follow-up the previous phase Ⅲ clinical trial of recombinant human follicle-stimulating hormone (Follitrope ?), and to evaluate the cumulative pregnancy rate, the cumulative live birth rate, and the neonatal outcomes of subjects. Methods:The phase Ⅲ clinical study of Follitrope ? in China (CTR20150341/CTR20150341, May 15, 2015—June 27, 2016) was followed up until December 31, 2022. Patients were divided into Follitrope ? group and Gonal-F ? group. According to the age, patients were divided into three subgroups: 20-30 years old subgroup, 31-35 years old subgroup and 36-39 years old subgroup. Cumulative pregnancy rate, cumulative live birth rate, number of embryos transferred per cycle, live births per embryo transfer cycle, live births per oocyte retrieved, and neonatal characteristics were analyzed. Results:A total of 446 patients were included in the analysis, of which 336 (75.3%) were in the Follitrope ? group and 110 (24.7%) in the Gonal-F ? group, with a follow-up period of 6.5 years. There were no statistically significant differences between the Follitrope ? group and the Gonal-F ? group in terms of cumulative pregnancy rate and cumulative live birth rate (all P>0.05). Similar cumulative pregnancy rates and cumulative live birth rates were observed between the two groups within each age subgroup (all P>0.05). In the 36-39 years old subgroup, the Follitrope ? group showed a trend towards higher cumulative pregnancy rate [60.0% (12/20)] and cumulative live birth rate [55.0% (11/20)] compared with the Gonal-F ? group [28.6% (2/7), 14.3% (1/7)], however, none of the differences were statistically significant (all P>0.05). Twin pregnancy rates, live births per embryo, live birth per oocyte, newborn gender, birth weight, and birth defect rates were similar between the Follitrope ? group and the Gonal-F ? group without statistically significant differences (all P>0.05). Conclusion:The safety and effectiveness of Follitrope ? in controlled ovarian hyperstimulation are similar to those of Gonal-F ?. Compared with Gonal-F ?, there is a trend toward higher cumulative pregnancy rates and cumulative live birth rates in elderly patients with Follitrope ?, although there is no statistical difference.

Objective: To evaluate the value of next-generation sequencing (NGS) in the prevention and management of thalassemia. Methods: A systematic search was performed in eight databases including China Biomedical Literature Database, Chinese National Knowledge Infrastructure, Chinese Scientific Journals Database, Wanfang database, PubMed, EMBASE, Web of Science, and Cochrane Library from the inception to 1 June 2022. Stata 17.0 and Review Manager 5.4 were used for the meta-analysis. Results: Nine studies containing 14794 participants were included in the meta-analysis. Compared with the routine genetic testing (including Gap-PCR and reverse dot blot), NGS had higher detection rates in screening thalassemia (RR 1.22, 95% CI 1.13-1.31, P<0.01), particularly for the α-thalassaemia mutation carriers (RR 1.24, 95% CI 1.07-1.44, P<0.01). However, no significant difference was found in the screening of β-thalassemia (RR 1.10, 95% CI 0.99-1.23, P>0.05). Conclusions: Compared with routine genetic testing, NGS had a higher detection rate in general, particularly in the detection of α-thalassemia.

Objective:To investigate whether the cyclosporin A (CsA) can improve the blastocyst implantation with mild impaired of trophoblast cells of mice.Methods:1) Totally 30 ICR mice were intraperitoneally injected with 5 mg/kg CsA, then the blood concentrations of CsA in mice were detected at 1 h, 3 h, 4 h, 6 h, 8 h, 10 h, 13 h, 14 h, 16 h and 20 h after administration using chemiluminescence method. 2) A total of 36 mice were randomly divided into control group and experimental group (CsA group); the experimental group was intraperitoneally injected with 5 mg/kg CsA and control group was injected with the equivalent dose olive oil of the same body weight. Embryos were classified into A, B, C types according to the guidelines of Gardner and experimental needs. Embryos were transferred to the uterus in the two groups. The embryo implantation rate was calculated and the leukemia inhibitory factor (LIF) mRNA level was measured by real time fluorescence quantitative PCR in 5.5 d postcoitum (dpc).Results:1) The blood concentration of CsA in mice reached a peak at 6-10 h after administration. 2) The embryo implantation rate of B type [73.9% (34/46)] had significantly improved in experimental group [50.0% (23/46), P=0.018]. 3) The expression of LIF mRNA level was not significantly different between the two groups ( P>0.05). Conclusion:When CsA was administered at a dose of 5 mg/kg, CsA can improve the embryo implantation rate with mild impaired trophoblast cells. CsA might become a potential drug to increase the success rates of the in vitro fertilization.

Objective:To investigate whether the cyclosporin A (CsA) can improve the blastocyst implantation with mild impaired of trophoblast cells of mice.Methods:1) Totally 30 ICR mice were intraperitoneally injected with 5 mg/kg CsA, then the blood concentrations of CsA in mice were detected at 1 h, 3 h, 4 h, 6 h, 8 h, 10 h, 13 h, 14 h, 16 h and 20 h after administration using chemiluminescence method. 2) A total of 36 mice were randomly divided into control group and experimental group (CsA group); the experimental group was intraperitoneally injected with 5 mg/kg CsA and control group was injected with the equivalent dose olive oil of the same body weight. Embryos were classified into A, B, C types according to the guidelines of Gardner and experimental needs. Embryos were transferred to the uterus in the two groups. The embryo implantation rate was calculated and the leukemia inhibitory factor (LIF) mRNA level was measured by real time fluorescence quantitative PCR in 5.5 d postcoitum (dpc).Results:1) The blood concentration of CsA in mice reached a peak at 6-10 h after administration. 2) The embryo implantation rate of B type [73.9% (34/46)] had significantly improved in experimental group [50.0% (23/46), P=0.018]. 3) The expression of LIF mRNA level was not significantly different between the two groups ( P>0.05). Conclusion:When CsA was administered at a dose of 5 mg/kg, CsA can improve the embryo implantation rate with mild impaired trophoblast cells. CsA might become a potential drug to increase the success rates of the in vitro fertilization.